27,778 Shares in Actuate Therapeutics (NASDAQ:ACTU) Acquired by Northwestern University

Northwestern University bought a new position in Actuate Therapeutics (NASDAQ:ACTU) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 27,778 shares of the company’s stock, valued at approximately $207,000. Actuate Therapeutics makes up about 0.2% of Northwestern University’s holdings, making the stock its 5th biggest position.

Separately, KG&L Capital Management LLC bought a new position in shares of Actuate Therapeutics during the third quarter valued at about $89,000.

Actuate Therapeutics Price Performance

NASDAQ ACTU opened at $8.94 on Friday. Actuate Therapeutics has a 1-year low of $5.51 and a 1-year high of $10.16. The firm has a 50-day moving average of $7.91.

Actuate Therapeutics (NASDAQ:ACTU) last announced its quarterly earnings data on Tuesday, September 24th. The company reported ($4.20) earnings per share for the quarter.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.